Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
DRUMMOND, MICHAEL
2007.
NICE: A nightmare worth having?.
Health Economics, Policy and Law,
Vol. 2,
Issue. 2,
p.
203.
Hartz, Susanne
and
John, Jürgen
2007.
Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play?.
SSRN Electronic Journal,
2007.
Assessing the economic challenges posed by orphan drugs: A comment on Drummond et al..
International Journal of Technology Assessment in Health Care,
Vol. 23,
Issue. 3,
p.
397.
Mitsumoto, Jun
Dorsey, E. Ray
Beck, Christopher A.
Kieburtz, Karl
and
Griggs, Robert C.
2009.
Pivotal studies of orphan drugs approved for neurological diseases.
Annals of Neurology,
Vol. 66,
Issue. 2,
p.
184.
Stolk, Pieter
Heemstra, Harald E
Leufkens, Hubert GM
Bloechl-Daum, Brigitte
and
Heerdink, Eibert R
2009.
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study.
Orphanet Journal of Rare Diseases,
Vol. 4,
Issue. 1,
Drummond, Michael
and
Sorenson, Corinna
2009.
Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom.
Value in Health,
Vol. 12,
Issue. ,
p.
S8.
Hartz, Susanne
and
John, Jürgen
2009.
Public health policy decisions on medical innovations: What role can early economic evaluation play?.
Health Policy,
Vol. 89,
Issue. 2,
p.
184.
Schlander, M.
and
Beck, M.
2009.
Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
Current Medical Research and Opinion,
Vol. 25,
Issue. 5,
p.
1285.
Drummond, Michael
and
Sorenson, Corinna
2009.
Can NICE Be Nicer? In a World of Budget Constraints There Are No Easy Solutions.
Value in Health,
Vol. 12,
Issue. 5,
p.
634.
Roll, Kathrin
Stargardt, Tom
and
Schreyoegg, Jonas
2010.
Authorization and Reimbursement of Orphan Drugs in an International Comparison (Zulassung Und Erstattung Von Orphan Drugs Im Internationalen Vergleich) (in German).
SSRN Electronic Journal,
McCabe, Christopher
Edlin, Richard
and
Round, Jeff
2010.
Rare Diseases Epidemiology.
Vol. 686,
Issue. ,
p.
211.
Goldman, Dana
Lakdawalla, Darius
Philipson, Tomas J.
and
Yin, Wesley
2010.
Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA.
Health Economics,
Vol. 19,
Issue. 10,
p.
1109.
Stockley, Robert A
Parr, David G
Piitulainen, Eeva
Stolk, Jan
Stoel, Berend C
and
Dirksen, Asger
2010.
Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry.
Respiratory Research,
Vol. 11,
Issue. 1,
López-Bastida, Julio
and
Oliva-Moreno, Juan
2010.
Rare Diseases Epidemiology.
Vol. 686,
Issue. ,
p.
273.
Orofino, Javier
Soto, Javier
Casado, Miguel A.
and
Oyagüez, Itziar
2010.
Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007.
Applied Health Economics and Health Policy,
Vol. 8,
Issue. 5,
p.
301.
O’Neill, Ciaran
2010.
How can the risk that orphan drugs present to budgets be managed better?.
Clinical Therapeutics,
Vol. 32,
Issue. 9,
p.
1640.
Verdian, Lara
and
Yi, Yunni
2010.
Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox–Gastaut Syndrome in the United Kingdom.
Seizure,
Vol. 19,
Issue. 1,
p.
1.
Blankart, Carl Rudolf
Stargardt, Tom
and
Schreyögg, Jonas
2011.
Availability of and Access to Orphan Drugs.
PharmacoEconomics,
Vol. 29,
Issue. 1,
p.
63.
Barak, Adam
and
Shankar Nandi, Jyoti
2011.
Orphan drugs: pricing, reimbursement and patient access.
International Journal of Pharmaceutical and Healthcare Marketing,
Vol. 5,
Issue. 4,
p.
299.
Refoios Camejo, Rodrigo
McGrath, Clare
and
Herings, Ron
2011.
A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
Health Policy,
Vol. 100,
Issue. 1,
p.
18.